Evolus reported Q2 2026 revenue that exceeded internal guidance, with top-line growth of 21% year-over-year. The company has raised its full-year 2026 revenue outlook, signaling confidence in sustained demand for its Jeuveau toxin and Evolus filler portfolio.
Business & M&A
Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook
The injectable platform company posts 21% revenue growth and signals sustained momentum in toxin and filler.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Evolus posts 21% revenue growth and raises 2026 guidance.
Evolus' trajectory—three consecutive profitable quarters and now accelerating revenue growth—marks a inflection point for the independent injectable platform. The company's strategy of bundled toxin-filler pricing and the Evolus Rewards loyalty program have gained traction with practices seeking alternatives to AbbVie and Galderma. At scale, Evolus' manufacturing footprint and supply-chain control offer margin advantages over pure-play distributors. The raised guidance suggests either stronger-than-expected adoption of Jeuveau in new markets or improved retention of existing customers. For practice owners, Evolus' momentum makes it a credible third option in toxin sourcing—particularly for high-volume practices where rebate leverage and supply reliability matter.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.